- Home
- SEAT vs AUTL Comparison
SEAT vs AUTL Comparison
Compare SEAT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- AUTL
- Stock Information
- Founded
- SEAT 2001
- AUTL 2014
- Country
- SEAT United States
- AUTL United Kingdom
- Employees
- SEAT N/A
- AUTL N/A
- Industry
- SEAT Industrial Machinery/Components
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEAT Industrials
- AUTL Health Care
- Exchange
- SEAT Nasdaq
- AUTL Nasdaq
- Market Cap
- SEAT 366.2M
- AUTL 625.4M
- IPO Year
- SEAT N/A
- AUTL 2018
- Fundamental
- Price
- SEAT $1.81
- AUTL $2.47
- Analyst Decision
- SEAT Buy
- AUTL Strong Buy
- Analyst Count
- SEAT 11
- AUTL 5
- Target Price
- SEAT $4.49
- AUTL $9.32
- AVG Volume (30 Days)
- SEAT 1.4M
- AUTL 1.8M
- Earning Date
- SEAT 08-05-2025
- AUTL 08-07-2025
- Dividend Yield
- SEAT N/A
- AUTL N/A
- EPS Growth
- SEAT N/A
- AUTL N/A
- EPS
- SEAT N/A
- AUTL N/A
- Revenue
- SEAT $748,757,000.00
- AUTL $9,011,000.00
- Revenue This Year
- SEAT N/A
- AUTL $461.76
- Revenue Next Year
- SEAT $4.42
- AUTL $112.66
- P/E Ratio
- SEAT N/A
- AUTL N/A
- Revenue Growth
- SEAT 0.82
- AUTL N/A
- 52 Week Low
- SEAT $1.44
- AUTL $1.11
- 52 Week High
- SEAT $5.74
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- SEAT 48.12
- AUTL 69.22
- Support Level
- SEAT $1.82
- AUTL $2.24
- Resistance Level
- SEAT $2.06
- AUTL $2.53
- Average True Range (ATR)
- SEAT 0.14
- AUTL 0.13
- MACD
- SEAT 0.02
- AUTL -0.00
- Stochastic Oscillator
- SEAT 45.65
- AUTL 88.55
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.